The Cancer Advisor

Keytruda - $29.5 billion Darzalex - $9 billion Opdivo - $7 billion Imbruvica - $5billion Tagrisso - $5 billion Revlimid - $4 billion Verzenio - $4 billion Imfinzi - $4 billion Ibrance - $3 billion Tecentriq - $3 billion In the rapidly evolving field of oncology, several cancer drugs have become best-sellers due to their proven effectiveness against various cancer types. Below, we examine some of the top-selling cancer drugs, highlighting their FDA-approved indications, mechanisms of action, and sales figures. 1. Keytruda (Pembrolizumab) - $29.5 billion Keytruda is the world's bestselling cancer drug by a large margin. (Merck & Co.) Company: Merck & Co. 2024 sales: $29.5 billion Indications Approved by FDA: Melanoma,  ( KEYNOTE-006 and KEYNOTE-054 trials) Non-small cell lung cancer,  ( KEYNOTE-010, KEYNOTE-407, KEYNOTE-189, KEYNOTE 671 trials) head and neck cancer,  ( KEYNOTE-012 and KEYNOTE-048) kidney cancer (renal cell carcinoma),  ( KEYNOTE-426) classical ...

William Makis; Ilyes Baghli; Pierrick Martinez (Corresponding Author) Case Rep Oncol (2025) 18 (1): 856–863. https://doi.org/10.1159/000546362 PubMed: 40605964 Abstract Background:  Fenbendazole (FBZ), an inexpensive and widely accessible antiparasitic drug used in veterinary medicine, has garnered growing interest for its potential as an anticancer therapy. Preclinical studies suggest that FBZ exerts its anticancer effects through a wide variety of mechanisms. While FBZ has shown promise both in vitro and in vivo studies, clinical evidence supporting its use and efficacy in treating metastatic cancer is currently limited.  Case Presentations:  This report highlights 3 cases of patients with advanced cancer – including breast, prostate, and melanoma. Two patients achieved complete remission, and one achieved near-complete remission after incorporating FBZ into their treatment regimens alongside other therapies (excluding chemotherapy). All three patients tolerated FBZ wit...